-DOCSTART- -X- O
BACKGROUND -X- _ O
: -X- _ O
The -X- _ O
common -X- _ O
cold -X- _ O
is -X- _ O
the -X- _ O
most -X- _ O
widespread -X- _ O
viral -X- _ O
infection -X- _ O
in -X- _ O
humans. -X- _ O
Iota-carrageenan -X- _ O
has -X- _ O
previously -X- _ O
shown -X- _ O
antiviral -X- _ O
effectiveness -X- _ O
against -X- _ O
cold -X- _ O
viruses -X- _ O
in -X- _ O
clinical -X- _ O
trials. -X- _ O
This -X- _ O
study -X- _ O
investigated -X- _ O
the -X- _ O
efficacy -X- _ O
of -X- _ O
a -X- _ O
carrageenan-containing -X- _ B-Intervention
nasal -X- _ I-Intervention
spray -X- _ I-Intervention
on -X- _ O
the -X- _ O
duration -X- _ O
of -X- _ O
the -X- _ O
common -X- _ B-Patient
cold -X- _ I-Patient
and -X- _ I-Patient
nasal -X- _ I-Patient
fluid -X- _ I-Patient
viral -X- _ I-Patient
load -X- _ I-Patient
in -X- _ I-Patient
adult -X- _ I-Patient
patients -X- _ I-Patient
. -X- _ O

METHODS -X- _ O
: -X- _ O
In -X- _ O
a -X- _ O
randomized -X- _ O
, -X- _ O
double-blind -X- _ O
, -X- _ O
placebo-controlled -X- _ O
trial -X- _ O
, -X- _ O
211 -X- _ B-Patient
patients -X- _ I-Patient
suffering -X- _ O
from -X- _ O
early -X- _ O
symptoms -X- _ O
of -X- _ O
the -X- _ O
common -X- _ O
cold -X- _ O
were -X- _ O
treated -X- _ O
for -X- _ O
seven -X- _ O
days. -X- _ O
Application -X- _ B-Intervention
was -X- _ I-Intervention
performed -X- _ I-Intervention
three -X- _ I-Intervention
times -X- _ I-Intervention
daily -X- _ I-Intervention
with -X- _ I-Intervention
either -X- _ I-Intervention
a -X- _ I-Intervention
carrageenan-supplemented -X- _ I-Intervention
nasal -X- _ I-Intervention
spray -X- _ I-Intervention
or -X- _ O
saline -X- _ B-Comparision
solution -X- _ I-Comparision
as -X- _ I-Comparision
placebo -X- _ I-Comparision
with -X- _ O
an -X- _ O
overall -X- _ O
observation -X- _ O
period -X- _ O
of -X- _ O
21 -X- _ O
days. -X- _ O
The -X- _ O
primary -X- _ O
endpoint -X- _ O
was -X- _ O
the -X- _ O
duration -X- _ O
of -X- _ O
disease -X- _ O
defined -X- _ O
as -X- _ O
the -X- _ O
time -X- _ O
until -X- _ O
the -X- _ O

last -X- _ O
day -X- _ O
with -X- _ O
symptoms -X- _ O
followed -X- _ O
by -X- _ O
all -X- _ O
other -X- _ O
days -X- _ O
in -X- _ O
the -X- _ O
study -X- _ O
period -X- _ O
without -X- _ O
symptoms. -X- _ O
During -X- _ O
the -X- _ O
study -X- _ O
, -X- _ O
but -X- _ O
prior -X- _ O
unblinding -X- _ O
, -X- _ O
the -X- _ O
definition -X- _ O
of -X- _ O
disease -X- _ O
duration -X- _ O
was -X- _ O
adapted -X- _ O
from -X- _ O
the -X- _ O
original -X- _ O
protocol -X- _ O
that -X- _ O
defines -X- _ O
disease -X- _ O
duration -X- _ O
as -X- _ O
the -X- _ O
time -X- _ O
period -X- _ O
of -X- _ O
symptoms -X- _ O
followed -X- _ O
by -X- _ O
48 -X- _ O
hours -X- _ O
without -X- _ O
symptoms -X- _ O
. -X- _ O

RESULTS -X- _ O
: -X- _ O
In -X- _ B-Outcome
patients -X- _ I-Outcome
showing -X- _ I-Outcome
a -X- _ I-Outcome
laboratory-confirmed -X- _ I-Outcome
cold -X- _ I-Outcome
virus -X- _ I-Outcome
infection -X- _ I-Outcome
and -X- _ I-Outcome
adherence -X- _ I-Outcome
to -X- _ I-Outcome
the -X- _ I-Outcome
protocol -X- _ I-Outcome
, -X- _ I-Outcome
alleviation -X- _ I-Outcome
of -X- _ I-Outcome
symptoms -X- _ I-Outcome
was -X- _ I-Outcome
2.1 -X- _ I-Outcome
days -X- _ I-Outcome
faster -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
carrageenan -X- _ I-Outcome
group -X- _ I-Outcome
in -X- _ I-Outcome
comparison -X- _ I-Outcome
to -X- _ I-Outcome
placebo -X- _ I-Outcome
( -X- _ I-Outcome
p -X- _ I-Outcome
= -X- _ I-Outcome
0.037 -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ I-Outcome
The -X- _ I-Outcome
primary -X- _ I-Outcome
endpoint -X- _ I-Outcome
that -X- _ I-Outcome
had -X- _ I-Outcome
been -X- _ I-Outcome
prespecified -X- _ I-Outcome
but -X- _ I-Outcome
was -X- _ I-Outcome
changed -X- _ I-Outcome
before -X- _ I-Outcome
unblinding -X- _ I-Outcome
was -X- _ I-Outcome
not -X- _ I-Outcome
met. -X- _ I-Outcome
Viral -X- _ I-Outcome
titers -X- _ I-Outcome
in -X- _ I-Outcome
nasal -X- _ I-Outcome
fluids -X- _ I-Outcome
showed -X- _ I-Outcome
a -X- _ I-Outcome
significantly -X- _ I-Outcome
greater -X- _ I-Outcome
decrease -X- _ I-Outcome
in -X- _ I-Outcome
carrageenan -X- _ I-Outcome
patients -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
intention-to-treat -X- _ I-Outcome
population -X- _ I-Outcome
( -X- _ I-Outcome
p -X- _ I-Outcome
= -X- _ I-Outcome
0.024 -X- _ I-Outcome
) -X- _ I-Outcome
and -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
per -X- _ I-Outcome
protocol -X- _ I-Outcome
population -X- _ I-Outcome
( -X- _ I-Outcome
p -X- _ I-Outcome
= -X- _ I-Outcome
0.018 -X- _ I-Outcome
) -X- _ I-Outcome
between -X- _ I-Outcome
days -X- _ I-Outcome
1 -X- _ I-Outcome
and -X- _ I-Outcome
3 -X- _ I-Outcome
/ -X- _ I-Outcome
4 -X- _ I-Outcome
. -X- _ O

CONCLUSIONS -X- _ O
: -X- _ O
In -X- _ B-Outcome
adults -X- _ I-Outcome
with -X- _ I-Outcome
common -X- _ I-Outcome
cold -X- _ I-Outcome
virus -X- _ I-Outcome
infections -X- _ I-Outcome
, -X- _ I-Outcome
direct -X- _ I-Outcome
local -X- _ I-Outcome
administration -X- _ I-Outcome
of -X- _ I-Outcome
carrageenan -X- _ I-Outcome
with -X- _ I-Outcome
nasal -X- _ I-Outcome
sprays -X- _ I-Outcome
reduced -X- _ I-Outcome
the -X- _ I-Outcome
duration -X- _ I-Outcome
of -X- _ I-Outcome
cold -X- _ I-Outcome
symptoms. -X- _ I-Outcome
A -X- _ I-Outcome
significant -X- _ I-Outcome
reduction -X- _ I-Outcome
of -X- _ I-Outcome
viral -X- _ I-Outcome
load -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
nasal -X- _ I-Outcome
wash -X- _ I-Outcome
fluids -X- _ I-Outcome
of -X- _ I-Outcome
patients -X- _ I-Outcome
confirmed -X- _ I-Outcome
similar -X- _ I-Outcome
findings -X- _ I-Outcome
from -X- _ I-Outcome
earlier -X- _ I-Outcome
trials -X- _ I-Outcome
in -X- _ I-Outcome
children -X- _ I-Outcome
and -X- _ I-Outcome
adults -X- _ I-Outcome
. -X- _ O

TRIAL -X- _ O
REGISTRATION -X- _ O
: -X- _ O
Current -X- _ O
Controlled -X- _ O
Trials -X- _ O
ISRCTN80148028 -X- _ O

